Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
about
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient CellsOncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer AscitesBiological Subtypes of Triple-Negative Breast Cancer.Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Anti-apoptotic effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, against multiple organ damage induced by gamma irradiation in rats.IER5 is involved in DNA Double-Strand Breaks Repair in Association with PAPR1 in Hela Cells.The development of PARP as a successful target for cancer therapy.CCDC6: the identity of a protein known to be partner in fusion.Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
P2860
Q33761920-D603EB2D-BA70-489B-9A50-D5BFBF9551E1Q33838956-4CA371E5-750A-4933-9707-C6D3E2D1A752Q33904378-9044691A-68BB-44D4-BF30-1DE40E6116F6Q39370768-0DA1FA83-2908-44E9-9618-28F502A540BCQ39393217-297988E6-CB1B-4790-A9B5-63591E374516Q39400469-D7F72673-DF66-4F3E-B342-B4233C114271Q42083096-5E6F8D4A-D5A8-4829-8B87-2B2C5AEACCE5Q45790068-8A08BB00-555F-44E7-BAF4-3DD7E4B4AE9BQ46823983-572FC6E4-257B-43A8-B2A9-5591D8382EE3Q47135345-D6C9F8E8-EA21-4A11-A0C0-6B03FC3B59B1Q47278103-8C385B64-2D98-49E4-B536-4668CC1B2A57Q47634740-73082BFD-16D5-4B4A-A4FB-2312D003182FQ49829001-A4709645-296B-44FF-B320-E9F19270EEFFQ49887888-639860E9-18C8-4DB3-9E67-F88B9C763687Q51800946-93CA41A5-3195-4340-9E33-1D9A75CC105DQ57492447-7842A95A-F6C9-419C-AD33-5928DF2A6C2B
P2860
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@ast
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@en
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@nl
type
label
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@ast
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@en
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@nl
prefLabel
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@ast
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@en
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@nl
P2093
P2860
P921
P1476
Use of poly ADP-ribose polymer ...... their inclusion in the clinic
@en
P2093
Angela Celetti
Aniello Cerrato
Francesco Morra
P2860
P2888
P356
10.1186/S13046-016-0456-2
P407
P5008
P577
2016-11-24T00:00:00Z
P6179
1052602162